Sign In
Buy KROS
$11.15
+0.500 (+4.69%)
At Close: Aug 07, 2026
Altium Capital Management LP Buys Keros Therapeutics Inc, Celldex Therapeutics Inc, X4 ...
09:38pm, Wednesday, 17'th Nov 2021 GuruFocus
Related Stocks: CLDX , OCUL , NVRO , CTMX , CERS , IMTX , KROS , XFOR , AFMD , BCYC , ARCT , BBIO , CHAQ , PALI , EPIX , ECOR , SIEN , BCTX ,
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions
01:00pm, Monday, 15'th Nov 2021 Intrado Digital Media
LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented results from a preclinical study of a research form of KER-012 (RKER-012) at the American Heart Association (AHA) 2021 Scientific Sessions held November 13 through 15, 2021.
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
LEXINGTON, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer
09:00am, Monday, 02'nd Aug 2021
LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
LEXINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, de
LEXINGTON, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics Announces Pricing of Public Offering of Common Stock
10:11pm, Thursday, 12'th Nov 2020
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics Announces Proposed Public Offering of Common Stock
05:12pm, Tuesday, 10'th Nov 2020
LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
04:17pm, Tuesday, 10'th Nov 2020
LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, dev
Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
04:01pm, Wednesday, 04'th Nov 2020
LEXINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
11:00am, Thursday, 13'th Aug 2020
LEXINGTON, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series
12:00pm, Monday, 10'th Aug 2020
LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, dev
